Perioperative chemotherapy for resectable gastric cancer – what is the evidence?
Sign Up to like & getrecommendations! Published in 2017 at "Scandinavian Journal of Gastroenterology"
DOI: 10.1080/00365521.2017.1293727
Abstract: Abstract The UK MAGIC trial published in 2006 was the first RCT to identify improved long-term survival rates using preoperative chemotherapy for resectable gastric or gastroesophageal cancer. Overnight, the treatment regimen impacted European guidelines. However,… read more here.
Keywords: chemotherapy; resectable gastric; survival rates; perioperative chemotherapy ... See more keywords
Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.895672
Abstract: Background Adjuvant chemotherapy has been shown to produce a favorable prognosis for patients with resectable mucosal melanoma (MM), resulting in the need for stratification to optimally select patients to benefit from adjuvant therapy. This study… read more here.
Keywords: index; melanoma; stratification; adjuvant chemotherapy ... See more keywords
Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.956755
Abstract: Background Several randomized studies have shown that the combination of programmed cell death 1 (PD-1) inhibitor and chemotherapy is efficacious as a treatment for advanced non-small-cell lung cancer (NSCLC). However, in the neoadjuvant setting, there… read more here.
Keywords: resectable squamous; squamous nsclc; inhibitors chemotherapy; chemotherapy resectable ... See more keywords